Epipodophyllotoxin (VP 16-213) in the treatmetn of diffuse histiocytic lymphoma.
Twenty-seven patients with diffuse histiocytic lymphoma, of whom 20 had failed to respond to all other forms of chemotherapy and radiotherapy, were treated with intravenous VP 16-213. Initial dramatic response was obtained in 5 (19%), good objective response in 12 (4%), and the remaining 10 (37%) either failed to respond or thad only minimal objective change in theri disease status. The response characteristically occured within two courses of therapy, but 8 of the 17 (47relapsed at this stage resulted in remission again begin achieved in these patients. It is concluded that VP 16-213 is an effective agent in diffuse histiocytic lymphoma, but it is of limited value when used as a single agent. This drug has surprisingly little myelotoxicity, and prospective studies are now in progress to evaluate its role in combination therapy.
D000328:Adult; D000368:Aged; D018288:Carcinoma, Small Cell / Q000188:drug therapy; D003520:Cyclophosphamide / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D007263:Infusions, Parenteral; D008175:Lung Neoplasms / Q000188:drug therapy; D016403:Lymphoma, Large B-Cell, Diffuse / Q000188:drug therapy*; D008228:Lymphoma, Non-Hodgkin / Q000188:drug therapy; D008297:Male; D008875:Middle Aged; D009362:Neoplasm Metastasis; D011034:Podophyllotoxin / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D011446:Prospective Studies; D012075:Remission, Spontaneous
D003520:Cyclophosphamide; D011034:Podophyllotoxin